Corvus reports Q3 2026 results, outlines soquelitinib pipeline milestones for 2027
Corvus says its Phase 3 PTCL and Phase 2 atopic dermatitis trials remain on track, with hidradenitis suppurativa and asthma studies advancing and cash runway extended into second quarter 2028.
SEC filing